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Background: Standardized ginseng extract has become the best-selling cold and ﬂu remedy in Canada, yet much controversy
regarding the eﬃcacy of ginseng in preventing common colds remains. Objective: To assess the eﬃcacy of ginseng preparations
for the prevention of common colds in healthy adults. Methods: Comprehensive bibliographic database, trial registry and grey
literature searches were conducted up to December 2007. Randomized controlled trials or controlled clinical trials comparing
North American (Panax quinquefolius)o rA s i a ng i n s e n g( Panax ginseng) root extract to placebo or no treatment in healthy adults
were included. Two reviewers independently applied the study selection criteria and assessed methodological quality. Results:F i v e
trialsinvolving747participantswereincluded.AllﬁvetrialsexaminedNorthAmericanginseng.Themethodologicalqualityofthe
trials varied widely. Ginseng preparations signiﬁcantly reduced the total number of common colds by 25% compared to placebo
(one trial; 95% CI: 5–45). There was a tendency toward a lower incidence of having at least one common cold or other acute
respiratory infection (ARI) in the ginseng group compared to the placebo group (ﬁve trials; relative risk: 0.70; 95% CI: 0.48–1.02).
Compared to placebo, ginseng signiﬁcantly shortened the duration of colds or ARIs by 6.2 days (two trials; 95% CI: 3.4–9.0).
Conclusions: There is insuﬃcient evidence to conclude that ginseng reduces the incidence or severity of common colds. North
American ginseng appears to be eﬀective in shortening the duration of colds or ARIs in healthy adults when taken preventatively
for durations of 8–16 weeks.
1.Introduction
Common colds are mild upper respiratory tract infections
that are characterized by coughing, nasal stuﬃness and
discharge, sneezing and sore throat. The common cold is one
of the most prevalent and widespread sources of morbidity
throughout the world, and adults experience an average of
two to four colds annually. Although the common cold is
generally a mild, self-limiting condition, it is associated with
a signiﬁcant economic burden due to medical costs and lost
work time [1].
Common colds are one of the most frequent conditions
for which natural health products are used [2]. One such
alternative remedy that has gained much popularity in
Canada during recent years is COLD-fX, a proprietary nat-
ural supplement isolated from North American ginseng root
(Panax quinquefolius). This ginseng preparation is heralded
as the “uncontested Canadian leader in the prevention of
colds” and has gained widespread use, such that it now
ranks as the country’s best-selling cold and ﬂu remedy [3].
However, much debate regarding the eﬃcacy of COLD-fX in
the prevention of common colds continues.
Recently, several clinical trials have investigated the
eﬃcacy of COLD-fX in reducing the incidence of common
colds in adults. The purpose of this review is to describe and
assess the evidence on the eﬃcacy of COLD-fX and other
North American or Asian ginseng root extracts in reducing
thenumber,severityanddurationofcommoncoldsandcold
symptoms in healthy adults.
2. Methods
2.1. Search Strategy. The research librarian (T.D.), in collab-
oration with the researchers, developed and implemented2 Evidence-Based Complementary and Alternative Medicine
search strategies designed to identify the highest level of
evidence available. Search terms were adapted appropriately
to search the following electronic databases from their
inception to December 2007: Alt HealthWatch (1990 to
present), AMED (1985 to present), CINAHL (1937 to
present), Cochrane Central Registerof Controlled Trials (3rd
Quarter, 2007), Cochrane Database of Systematic Reviews
(Issue 2, 2007), Database of Abstracts of Reviews of Eﬀects
(1994 to present), EMBASE (1988 to present), Evidence-
based Complementary Medicine (2005 to present), Interna-
tional Pharmaceutical Abstracts (1970 to present), Natural
Standard, OCLC PapersFirst and ProceedingsFirst (1993
to present), Ovid MEDLINE (1950 to present), ProQuest
Dissertations and Theses (1861 to present), BIOSIS Previews
(1969 to present), Science Citation Index Expanded (1900 to
present)andSocialSciencesCitationIndex(1956topresent).
The appendix outlines the MEDLINE search terms and
strategy that were subsequently adapted to accommodate the
controlled vocabulary and search language of each database.
Trial registers including ClinicalTrials.gov, Current Con-
trolled Trials metaRegister, National Research Register and
complementary and alternative medicine websites includ-
ing HerbMed, NCAM (National Center for Complemen-
tary and Alternative Medicine) (http://nccam.nih.gov),
NIH Oﬃce of Dietary Supplements (http://ods.od.nih.gov),
CAMEOL (Complementary and Alternative Medicine Evi-
dence OnLine) (http://www.rccm.org.uk/cameol/Default
.aspx) and IBIDS (International Bibliographic Information
on Dietary Supplements) (http://ods.od.nih.gov/Health
Information/BIDS.aspx) were searched for additional trials
and unpublished literature.
2.2. Study Selection. Randomized controlled trials (RCT)
and controlled clinical trials (CCT) were eligible for inclu-
sion in this review. Participants in the primary studies were
required to be adults (≥18 years) and be in good general
health, as deﬁned by the trial authors. Studies were con-
sidered for inclusion if participants in the treatment group
received either: (i) COLD-fX, a proprietary standardized
extract of North American ginseng root (CV Technologies
Inc., Edmonton, Canada) or (ii) oral preparations of other
root extracts of North American (Panax quinquefolius)o r
Asian ginseng (Panax ginseng). In trials using American or
Asian ginseng root extracts other than COLD-fX, ginseng
had to be the primary active ingredient. Appropriate com-
paratorswereplaceboornotreatment.Thestudiesidentiﬁed
in the search were initially screened for broad relevance
by one reviewer (S. K.) based on their titles and abstracts.
Subsequently, the full publications were retrieved and two
reviewers (J. K. S. and S. K.) independently assessed the
eligibility of potentially relevant trials using a standardized
form. Disagreements were resolved by consensus.
2.3. Outcomes. The primary outcome was the incidence of
common colds throughout the trial period. “Cold” was
classiﬁed using the deﬁnition of the trial authors. Secondary
outcomes included the severity, duration of colds, cold
symptoms and adverse events. Trials that reported the com-
bined incidence of any acute respiratory infections (ARIs)
including common colds, such as the combined incidence of
either cold or inﬂuenza, instead of measuring occurrences of
common colds separately, were also included in the review.
2.4. Quality Assessment. T w or e v i e w e r s( J .K .S .a n dS .
K.) independently assessed the methodological quality of
each included trial with the validated Jadad scale [4].
Concealment of treatment allocation was assessed using the
criteria of Schulz and colleagues [5]. Disagreement between
the reviewers regarding the quality ratings was resolved
through discussion.
2.5. Data Extraction. Data were extracted independently by
tworeviewers(J.K.S.andS.K.).Astandardizedpaper-based
extraction form was used to collect details regarding the
study design, population, intervention, measured outcomes
and other relevant study characteristics (e.g. source of
funding, language of publication, etc.). Agreement between
the reviewers was conﬁrmed prior to entering data.
2.6. Data Analysis. Analysis was conducted using Review
Manager4.2[6].Meta-analysiswasperformedtopoolresults
across several trials where the population, intervention,
comparison group and outcome were considered to be
comparable. The I2 statistic was used to assess all the
pooled estimates for heterogeneity. Continuous outcomes
were combined using a weighted mean diﬀerence, and the
inverse variance method was used to assign weights to the
trials. Relative risk for harm was used for the dichotomous
outcome, and the Mantel-Haenszel method was used to
assign weights to the trials [7].
For all meta-analyses, a random eﬀects model was
used. For each outcome measure, a point estimate and its
respective95%conﬁdenceinterval(95%CI)werecalculated.
A forest plot was created for outcomes for which the results
of two or more studies were pooled.
A subgroup analysis was planned ap r i o r ito compare
trials using North American ginseng extracts to those using
Asian ginseng extracts. Similarly, a sensitivity analysis was
planned to compare the respective inﬂuence of studies of
high and low quality. There was an insuﬃcient number of
trials to construct a funnel plot or to conduct a quantitative
analysis to assess for publication bias.
3. Results
3.1. Study Selection. A ﬂow diagram of the retrieval and
selection process is shown in Figure 1. Independent review
of the 37 potentially relevant studies identiﬁed ﬁve relevant
RCTs published in four articles [8–11]. The paper by
McElhaney and colleagues in 2004 [8] reported two separate
parallel-arm RCTs conducted during two inﬂuenza seasons
(8- and 16-week duration, resp.); the two trials are reported
separately in this analysis (McElhaney 2004a and McElhaney
2004b). References of the excluded studies are available on
request to the corresponding author.
A single ongoing study was identiﬁed through Clin-
icalTrials.gov. This trial examines the eﬀectiveness of aEvidence-Based Complementary and Alternative Medicine 3
722 citations identiﬁed from
electronic database search
685 citations excluded at
screening
37 potentially relevant full-text
articles retrieved for further review
33 articles excluded:
No RCT (N=27)
Inappropriate population (N=1)
Inappropriate intervention (N=2)
Inappropriate outcome (N=1)
Duplicate report of same trial (N=2)
4 relevant articles reporting 5 RCTs
0 relevant articles identiﬁed
from grey literature search
Figure 1: Flow diagram of study search and inclusion.
single 800mg dose of COLD-fX in preventing respiratory
infections compared to a placebo in healthy adult employees
of continuing care facilities. The expected completion date
was April 2006. No additional information regarding this
study could be retrieved.
3.2. Study Characteristics. The characteristics of the included
trials are shown in Table 1. All of the ﬁve included trials
were parallel-arm RCTs and were published in English
between 1996 and 2006. Four of the RCTs [8, 10, 11] exam-
ined the eﬃcacy of COLD-fX [a poly-furanosyl-pyranosyl-
saccharide-rich extract of North American ginseng root
(Panax quinquefolius)] in the prevention of colds compared
to placebo, while the remaining trial [9] compared the
prophylactic use of Ginsana G115 [a standardized extract of
Asian ginseng root (Panax ginseng)] to placebo. All of the
four COLD-fX trials were conducted in Canada and funded
by the manufacturer, while the Ginsana trial was conducted
in Italy and did not specify its source of funding. There
was clinical heterogeneity among the ﬁve trials. Three trials
included primarily elderly populations, with mean ages over
65 years [8, 11], while the remaining two trials examined
middle-aged individuals [9, 10]. The settings included long-
term care facilities in two [8] and communities in three trials
[9–11], respectively.
Table 2 indicates the methodological quality ratings for
each study on the components of the Jadad scale and on the
allocation concealment criterion. Overall, methodological
quality was quite variable: two studies had high-quality
scoresusingboththeJadadcriteria(ratedas5/5)andSchulz’s
allocation concealment criteria (rated adequate) [10, 11]. In
contrast, the remaining three studies had much lower quality
scores, ranking 2/5 on the Jadad scale and with unclear
allocation concealment [8, 9]. The agreement between the
reviewers in assessing quality was high (κ = 0.86).
3.3. Eﬃcacy. Only one trial [10]r e p o r t e do u t c o m e ss p e c i ﬁ c
to the common cold while the remaining four trials [8, 9, 11]
reported combined data for ARIs including common colds.
Therefore, both outcomes speciﬁc to common colds and
those related to ARIs were combined in our analysis.
3.3.1. Primary Outcome. Five studies reported the propor-
tion of participants who experienced at least one common
cold or ARI throughout the duration of the study. The inci-
dence of common colds and other ARIs are shown together
in the Figure 2. The relative risk of acquiring at least one
common cold or ARI was 0.70 (95% CI: 0.48–1.02) for study
periods ranging from 8 to 16 weeks (Figure 2), with a large
amount of heterogeneity (I2 = 68.5 % ) .T h et r i a l sf a v o r e d
ginseng, with the exception of one [8], which showed no
advantage of ginseng over placebo (relative risk 1.0). How-
ever, the size of the eﬀect varied substantially across the trials
and there was little overlap in the CIs between the studies.
The number of common colds throughout the study
period was measured as a continuous outcome in one of
the included trials [10]: Predy et al. found a statistically
signiﬁcant reduction of 25% (95% CI: 5–45%) in the total
number of Jackson-veriﬁed colds experienced by the group
taking COLD-fX compared to those taking the placebo.
Jackson-veriﬁed colds were deﬁned as a 2-day total symptom
score greater than 14, where participants self-rated 10 cold
symptoms on a scale ranging from 0 (no symptom) to 3
(severe symptom).
3.3.2.SecondaryOutcomes. Onlyonestudy[10]reportedthe
eﬀect of COLD-fX on the severity of cold symptoms. Daily,
participants rated the severity of 10 cold symptoms (e.g. sore
throat, runny nose, cough etc.) using a 4-point scale for each
symptom, where a score of 0 indicated no symptom and 3
indicated severe symptom. The mean diﬀerence in the total
symptom severity scores between the ginseng and placebo
groups was −11.70 points over the 4-month study duration
(95% CI: −33.69–10.29).
ThedurationofcoldsandARIswasreportedintwotrials
[10, 11]. Colds or ARIs in the ginseng group were an average4 Evidence-Based Complementary and Alternative Medicine
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Table 2: Methodological quality of included studies according to Jadad et al. [4] and Schultz et al. [5].
Reference Described as
randomized
Randomization
well described
and appropriate
Outcome
assessment
blinded
Blinding well
described and
appropriate
Description of
withdrawals
and drop-outs
Total Jadad
score
Allocation
concealment
McElhaney et al.
[8], trial A Yes No Yes No No 2/5 Unclear
McElhaney et al.
[8], trial B Yes No Yes No No 2/5 Unclear
McElhaney et al.
[11] Yes Yes Yes Yes Yes 5/5 Adequate
Predy et al. [10] Yes Yes Yes Yes Yes 5/5 Adequate
Scaglione et al.
[9] Yes No Yes No No 2/5 Unclear
Study
or sub-category
Ginseng
n/N
Placebo
n/N
RR (random)
95% Cl
Weight
%
RR (random)
95% Cl
McElhaney 2006
McElhaney 2004-A
McElhaney 2004-B
Scaglione 1996
Predy 2005
7/22
15/40
18/57
15/114
71/130
13/21
18/49
18/52
42/113
95/149
14.79
18.65
18.89
19.04
28.63
100.00
0.51 [0.26, 1.03]
1.02 [0.59, 1.76]
0.91 [0.53, 1.56]
0.35 [0.21, 0.60]
0.86 [0.70, 1.04]
0.70 [0.48, 1.02] 384
0.1 0.2 0.5 1 2 5 10
Favours ginseng Favours placebo
363 Total (95% Cl)
Total events: 126 (ginseng), 186 (placebo)
Test for heterogeneity: Chi2 = 12.71, df = 4( P = .01), P = 68.5%
Test for overall eﬀect: Z = 1.88 (P = .06)
(a)
Study
or sub-category
Ginseng
Mean (SD) Mean (SD) N
71 3
73 96
109 80
5.60 (2.90)
10.80 (9.70)
12.60 (7.60)
16.50 (13.80)
N
Placebo RR (random)
95% Cl
Weight
%
RR (random)
95% Cl
McElhaney 2006
Predy 2005
10
36.70
63.30
100.00
5 0
Favours control Favours treatment
Total (95% Cl)
−7.00[−11.66,−2.34]
−5.70[−9.25,−2.15]
−6.18[−9.00,−3.36]
−5 −10
Test for heterogeneity: Chi2 = 0.19, df = 1( P = .66), P = 0%
Test for overall eﬀect: Z = 4.29 (P<. 0001)
(b)
Figure 2: Forest-plot of incidence of having at least one cold or ARI (a) and duration of cold/ARI (b).
of 6.2 days (95% CI: 3.4–9.0) shorter than in the placebo
group (Figure 2). Heterogeneity between these two studies
was negligible (I2 = 0%).
Adverse events were assessed in all ﬁve trials. The overall
incidence of adverse events reported varied widely from 4%
[8] to 92% [8]. No trial found a statistically signiﬁcant diﬀer-
ence in the incidence of adverse events with the exception of
Scaglioneetal.[9](7%intheginsenggroupversus1%inthe
placebo group, P = .04). The most common type of adverse
event in all of the trials was “gastrointestinal symptoms”,
reported in up to 45% of participants in one trial [8].
3.3.3. Subgroup and Sensitivity Analyses. An ap r i o r isub-
group analysis was performed to examine whether the
relative risk of acquiring a common cold diﬀers between
the four trials using COLD-fX [7, 9, 10], a standardized
extract of North American ginseng, and the one study using
Ginsana G115 [9], an Asian ginseng extract. The relative risk
ofcoldorARIusingCOLD-fXwas0.85(95%CI:0.72–1.01),
while the relative risk using Ginsana G115 was 0.35 (95% CI:
0.21–0.60). Deeks’ method indicated that the type of ginseng
used (COLD-fX versus G115) was a signiﬁcant factor for
explaining heterogeneity between the trials (Q = 10.2, P =
.001), where prophylactic use of Ginsana G115 was favored.
A sensitivity analysis for methodological quality indi-
cated that high quality studies, scoring 5/5 on the Jadad
scale [10, 11], had a relative risk of 0.74 (95% CI: 0.47–
1.17) for acquiring a cold or ARI, while the remaining, low-
quality studies (Jadad score of 2/5) had a relative risk of 0.69
(95% CI: 0.35–1.35) [8, 9]. Therefore, trials of high quality
in this sample tended to have a more conservative estimate
of treatment eﬀect compared to trials of lower quality.6 Evidence-Based Complementary and Alternative Medicine
The heterogeneity was much greater between the studies of
low quality (I2 = 78.8) and those of high quality (I2 =
48.2). However, methodological quality was not signiﬁcant
in explaining heterogeneity (Q = 1.34, P = .247).
4. Discussion
The current review assessed the eﬃcacy of preparations
of North American and Asian ginseng extracts for the
prevention of common colds. The incidence of common
colds or ARIs in the ginseng group compared to placebo was
assessed in ﬁve studies, yielding a nonsigniﬁcant 30% reduc-
tion favoring the ginseng group. However, methodological
quality varied widely and there was little consistency in the
size or precision of the eﬀect. Pooling the results of two
trials that assessed the duration of cold and ARI symptoms
showed a statistically signiﬁcant reduction by 6.2 days when
comparing ginseng versus placebo.
The present review had set out to investigate the eﬀect
of ginseng extracts on preventing the common cold, yet
the majority of the trials reported only prevention of
ARIs including colds. Therefore, the results can only be
applied to ARIs in general, including more severe illnesses
such as inﬂuenza, rather than the common cold alone. In
addition, there was limited data available to address the
eﬀect of ginseng on cold duration and symptom severity,
and the methodological quality of the included studies
variedsubstantially.Alltrialshadrestrictiveeligibilitycriteria
with regard to medical conditions, medications taken and
other factors such as smoking and pregnancy. Therefore,
the results of this review may only be reﬂective of healthy
adults who do not have certain risk factors for colds and
ARIs (e.g. smoking), and the eﬀect may diﬀer greatly in
more vulnerable populations. In addition, a substantial
proportion of the participants were elderly individuals,
therefore caution should be used when generalizing the
results of the pooled analyses to populations of younger
adults. Finally, there was little consistency in the magnitude
of the point estimate and minimal overlap of the conﬁdence
intervals across the trials. Considering the few number of
trials and participants, the heterogeneous study populations,
the varying methodological quality and the inconsistency of
results between the trials, care must be taken in interpreting
the eﬃcacy of COLD-fX and G115 in cold prevention.
COLD-fX is marketed for long-term use for cold pre-
vention as well as 3-day high-dose use when individuals
perceive the onset of a cold. The currently available data
are insuﬃcient to support the use of COLD-fX for the
prevention of common colds. The authors were unable to
identify any past or current trials that examine the eﬃcacy
of short-term use of COLD-fX in the treatment of colds
which have already begun. However, COLD-fX appears to
be eﬀective in reducing the duration of ARIs after onset,
showingameandecreaseof6daysinthelengthofcolds/ARIs
of the COLD-fX group compared to the placebo group.
This result was statistically signiﬁcant, however, it should
be noted that this ﬁnding was based on only two trials
whose populations were heterogeneous in terms of age. The
heterogeneity of the populations and small sample size of
one of the pooled studies may have contributed to the wide
conﬁdence interval of the estimate (Figure 2).
The eﬃcacy of ginseng extracts must also be considered
in light of potential adverse eﬀects, which might occur
as a result of its daily use. All studies reported adverse
events and their frequency varied widely between the trials
with the chief complaint being “gastrointestinal symptoms”.
Two subjects in the ginseng group in the Predy et al. [10]
trial developed type 2 diabetes during the study and were
subsequently withdrawn. There was no information as to
whether these adverse events were deemed to be related to
ginseng. In the other four trials, no serious adverse events
related to ginseng were reported. However, there is need
for a systematic investigation of any harmful eﬀects that
might result from prolonged and frequent ingestion of these
standardized ginseng extracts.
Further trials on the eﬀect of ginseng extracts on the
common cold and other ARIs are needed, especially on the
short-termtherapeuticuseforwhichCOLD-fXisadvertised.
The majority of the trials identiﬁed in this review did not
use systematic criteria in deﬁning the presence of common
cold. Future trials should classify the occurrence of colds
using a validated instrument, as this would likely decrease
the potential for misclassiﬁcation bias.
5. Conclusions
Currently, there is insuﬃcient evidence to support the use
of North American ginseng extracts in the prevention of
common colds. While there was a trend toward a lower risk
of developing at least one common cold in the ginseng group
compared to the placebo group across the ﬁve trials, this
result must be interpreted with caution due to inconsistency
in the size of the eﬀect and precision, as well as the varying
quality of the included studies. There is some evidence
consistent across two trials that the duration of colds and
otherARIsisdecreasedbyanaverageof6daysforindividuals
taking the ginseng extract COLD-fX.
Appendix
MEDLINE (Ovid) Search Strategy
Version: OvidSP UI1.0.1
1950 to November Week 2 2007
Adapted for controlled vocabulary of other electronic
databases searched
(1) exp Panax/
(2) Plant Extracts/
(3) Drugs, Chinese Herbal/
(4) Plants, Medicinal/
(5) Phytotherapy/
(6) Plant Preparations/
(7) Plant Roots/
(8) Medicine, Herbal/Evidence-Based Complementary and Alternative Medicine 7
(9) Polysaccharides/
(10) (poly-furanosyl-pyranosyl-saccharide? or
polyfuranosyl-pyranosyl saccharide? or
polyfuranosyl-pyranosylsaccharide?).mp. [mp =
title, original title, abstract, name of substance word,
subject heading word]
(11) (COLD-fX or Cold fX or ColdfX).mp. [mp = title,
original title, abstract, name of substance word,
subject heading word]
(12) (CVT-E002 or CVT E002 or CVTE002).mp. [mp =
title, original title, abstract, name of substance word,
subject heading word]
(13) (CNT-2000 or CNT 2000 or CNT2000).mp. [mp =
title, original title, abstract, name of substance word,
subject heading word]
(14) (G-115 or G115).mp. [mp = title, original title,
abstract, name of substance word, subject heading
word]
(15) ginseng$.mp.
(16) panax.mp.
(17) or/1–16
(18) Common Cold/
(19) Respiratory Tract Infections/
(20) Respiratory Syncytial Virus, Human/
(21) cold$.mp.
(22) (common adj5 cold$).mp.
(23) (respiratory adj5 (infection? or illness$)).mp.
(24) URTI?.mp.
(25) ARI?.mp.
(26) or/18–25
(27) 17 and 26
(28) Animals/
(29) Humans/
(30) 28 not (28 and 29)
(31) 27 not 30
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